Some persons have reported serious adverse effects from the increasing usage of GLP-1 medications and comparable pharmaceuticals to treat type 2 diabetes and, in some circumstances, obesity. The makers of the popular weight reduction medications, Novo Nordisk and Eli Lilly, are currently being sued.
Semaglutide and tirzepatide are two injectable drugs that work by decreasing the rate at which the stomach empties its contents. In very unusual situations, a condition known as gastroparesis (or “stomach paralysis”) may develop when the stomach has trouble emptying. Medical Offices of Manhattan gastroenterologist Dr. Shilpa Mehra Dang discusses the current status of these medications. Read the article.
